Business
Scancell to present three posters at ICI
Scancell to present three posters at ICI.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n\n14 September 2023\n \nScancell Holdings plc\n(\"Scancell\" or the \"Company\")\n \n \nScancell to present three posters at the Seventh International Cancer Immunotherapy Conference\n \nScancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, announces it will present three posters at the Seventh International Cancer Immunotherapy Conference, jointly organised by the American Association for Cancer Research, the European Network for Cancer Immunotherapy and the Cancer Research Institute and taking place on 20-23 September 2023 in Milan, Italy.\n \nProf Lindy Durrant, Chief Executive Officer and Chief Scientific Officer of Scancell, commented: \"We look forward to presenting at such a prestigious meeting and sharing data on our preclinical programmes with the scientific community. As previously disclosed in a recent business update, we continue to make great progress in the clinic with our two lead cancer vaccine assets SCIB1/iSCIB-1+ and Modi-1 currently in Phase 1/2 clinical trials as well as leveraging the value of our antibody platform to generate revenue through high value licence agreements.\n \n\"Showcasing the potential of our technology platforms to generate further pipeline assets with high value partnering opportunities, we will be presenting encouraging data on both the Moditope® and GlyMab® platforms. Data on antibody candidates derived from the GlyMab® platform illustrate the potential of these assets as chimeric antigen receptor T cell (CAR-T) therapies and could lead to out licensing opportunities with cell therapy companies. Furthermore, we will be presenting data bolstering the potential of Modi-2 as a solid tumour cancer therapy and further characterising the response to Moditope® peptides in preclinical studies.\"\n \nThe title, timing and location of the poster presentation are as follows:\n \nPoster 1\n \n\n\n\nPoster presentation title\n\n\nAnti-sialyl-di-lewisa CAR T cells for effective anti-tumour therapy\n\n\n\n\nAuthors\n\n\nIniobong Charles, Katherine Cook, Bubacarr Kaira, Gaëlle Cane, Anne Skinner, Alissa Wright, Mireille Vankemmelbeke, Rachael Metheringham, Victoria Brentville and Lindy Durrant\n\n\n\n\nSession title\n\n\nPoster Session A\n\n\n\n\nSession date and time\n\n\n12.30 - 14....